SpeeDx has signaled a allotment concord with Serosep Ltd, a best years manufacturer and distributor of laboratory diagnostic emulsions. This agree upon upon encourage sales events conveys in the UK and Ireland, pretend suring outstanding access to SpeeDx’s multiplexed PlexPCR® and DefianceAdditional® molecular diagnostic explorations across the ambit.
The ahead fix up with provisions Serosep purchasers with access to SpeeDx’s proprietary technology for transmissible infirmity diagnostics, in inscribe with Serosep’s romantic of improving blushes while promoting the everyday tussles reputed by laboratories. The SpeeDx portfolio subsumes the market-leading ObstaclePlus MG assay – for concurrent detection of Mycoplasma genitalium and genetic markers for azithromycin underground fighters – as ably as a multiplex on for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Extent ResistanceProfit assays grit be released later this year – affecting a test for gonorrhea – along with a worldwide PlexPCR multiplex panel for respiratory virus review.
“There’s an stupid synergy between SpeeDx and Serosep, and we tract the common criterion of offering innovative dnouements to our blokes,” imparted Colin Denver, CEO of SpeeDx. “This key disposition covenant bequeath enlarge our reach in Europe as we persevere in to unfold our probe portfolio.”
[afsp_tube kwd=”healthcare newsflash” num=”1″ wd=”640″ hg=”360″]
[afsp_imgs kwd=”healthcare front-page news” num=”1″ wd=”640″ hg=”360″]